BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21981678)

  • 21. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
    Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
    Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
    Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
    Cohen MB; Rokhlin OW
    J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
    J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
    Yang L; Egger M; Plattner R; Klocker H; Eder IE
    Urology; 2011 Jun; 77(6):1508.e1-7. PubMed ID: 21624609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells.
    Iguchi K; Toyama T; Ito T; Shakui T; Usui S; Oyama M; Iinuma M; Hirano K
    J Androl; 2012; 33(6):1208-15. PubMed ID: 22700762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
    Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
    Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
    Liu W; Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
    J Med Chem; 2012 Jan; 55(2):971-5. PubMed ID: 22175694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity
    Dart DA; Kandil S; Tommasini-Ghelfi S; Serrano de Almeida G; Bevan CL; Jiang W; Westwell AD
    Mol Cancer Ther; 2018 Sep; 17(9):1846-1858. PubMed ID: 29895558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.